ACR Perspectives
View all perspectives
Dr. John Cush RheumNow
1 year 5 months ago
“Hey PRESTO!” – Early identification of psoriatic arthritis
The past decade has seen the management of psoriatic arthritis (PsA) transform, with our rich therapeutic armamentarium truly revolutionising patient outcomes.
https://t.co/FJNX3mGCoy https://t.co/Whd8QKwmkU
Dr. John Cush RheumNow
1 year 5 months ago
Effect of voclosporin in class V lupus nephritis
Dr. Yusof ( @Yuz6Yusof) discusses abstract 0355 presented at #ACR22. Abstract 0355: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study
https://t.co/v716QGx73g https://t.co/ANTOEDAAHt
Dr. John Cush RheumNow
1 year 5 months ago
The CONSUL Trial: Ankylosing Spondylitis
Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract 0546 presented at #ACR22.
https://t.co/DXTn3XfEzC https://t.co/pbORtBsRm2
Dr. John Cush RheumNow
1 year 5 months ago
JAK vs TNF inhibitor Infections in RA
Dr. David Liew ( @drdavidliew) discusses abstract 0302 at #ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
https://t.co/GsOsWtuT7v https://t.co/GloKEcB75L
Dr. John Cush RheumNow
1 year 5 months ago
Does BASDAI work for women?
In Abstract 0406 S. Maguire et al sought to understand if BASDAI and BASFI captured disease activity and quality of life in female axSpA patients.
Read more from Dr. Rachel Tate ( @uptoTate ) #ACR22
https://t.co/yWzdRMPgpp https://t.co/YrMsAYbAWN
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
In abstract 0001 presented at ACR22 Convergence, researchers presented 12-month data from a randomized double-blind placebo-controlled trial of pegloticase with or without MTX.
Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus. However, outcomes of therapies within the same class (i.e. BAFF-inhibitor) when evaluated in randomised controlled trials have been inconsistent.
Dr. John Cush RheumNow
1 year 5 months ago
ACR Best Abstracts - Day 3
The last day was jammed with important reports and research including the late breaking abstracts. These were some of our favorites. #ACR22
https://t.co/vUrxBTF3Wj https://t.co/QKpTjyFfxt
Eric Dein ericdeinmd
1 year 5 months ago
#ACR22 final plenary session
10 week study outcomes of Philly vs Placebo to be reported
#rheumpix @RheumNow https://t.co/BradH2Ty70
Poster Hall